Biliary Tract Cancer
If it’s your first time on this website, please read the disclaimer section.
Jul 06 – Jul 13, 2026
Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer: A Post Hoc Analysis of the TOPAZ-1 Randomized Clinical Trial.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This post hoc analysis of the phase 3 TOPAZ-1 trial evaluated the 4-year overall survival (OS) and safety of durvalumab plus gemcitabine and cisplatin (GemCis) as a first-line treatment for advanced biliary tract cancer (aBTC). Among 685 randomized participants, median OS was 13.0 months for durvalumab plus GemCis versus 11.4 months for placebo plus GemCis (HR, 0.75), with a 48-month OS rate of 11.8% vs 4.3%, respectively. The study demonstrates a long-term survival benefit for a specific cancer type, directly aligning with the clinician’s interest in cancer research. These findings reinforce durvalumab plus GemCis as a first-line standard of care for aBTC, offering improved patient outcomes with a manageable safety profile.
10.1001/jamaoncol.2026.2204
Jun 29 – Jul 06, 2026
Robotic versus Open Pancreatoduodenectomy (PORTAL): multicentre, single masked, phase 3, non-inferiority randomised controlled trial.
BMJ-BRIT MED J · Q1 JOURNAL - RANK #5/332TOP-TIER
This phase 3 non-inferiority RCT compared robotic (RPD) versus open pancreatoduodenectomy (OPD) in 268 adults with resectable pancreatic or periampullary disease across seven Chinese high-volume centers. The primary outcome, time to postoperative functional recovery, was significantly shorter with RPD (restricted mean event time 12.1 vs 16.0 days; difference -3.9 days, P<0.001). RPD also showed lower overall morbidity (31.1% vs 36.1%) and fewer Clavien-Dindo ≥II complications (23.5% vs 34.4%), though operative time and total costs were higher. For clinicians focused on cancer, the study directly addresses surgical management of resectable pancreatic cancer, demonstrating non-inferior oncological safety with faster recovery in specialized centers.
10.1136/bmj-2026-319692
Jun 01 – Jun 08, 2026
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase 3 randomized trial (FIGHT-302) evaluated the efficacy and safety of first-line pemigatinib compared to gemcitabine plus cisplatin chemotherapy in 167 adults with advanced FGFR2-rearranged cholangiocarcinoma. Pemigatinib significantly improved median progression-free survival to 8.3 months compared to 6.8 months for chemotherapy (HR 0.58; p=0.0078), with a notably higher objective response rate of 47% versus 15%. Although median overall survival was similar between groups (24.4 vs. 25.0 months), pemigatinib demonstrated a superior duration of response (14.2 vs. 6.3 months) with a safety profile consistent with previous findings. These results support pemigatinib as a potent first-line targeted therapy option for patients with this specific genetic rearrangement, offering a non-chemotherapeutic alternative with improved progression control.
10.1200/JCO-26-00788